Full Text | PDF

Theranostics 2012; 2(4):392-402. doi:10.7150/thno.3722 This issue Cite

Review

Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back

Byeong-Cheol Ahn^✉

Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, South Korea

✉ Corresponding author: Byeong-Cheol Ahn, MD, PhD, Professor and Director, Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, 50 Samduck 2-Ga, Jung Gu, Daegu, South Korea 700-412. Tel: 82-53-420-5583; Fax: 82-53-422-0864; E-mail: abc2000ac.kr More

Abstract

Molecular imaging, defined as the visual representation, characterization and quantification of biological processes at the cellular and subcellular levels within intact living organisms, can be obtained by various imaging technologies, including nuclear imaging methods. Imaging of normal thyroid tissue and differentiated thyroid cancer, and treatment of thyroid cancer with radioiodine rely on the expression of the sodium iodide symporter (NIS) in these cells. NIS is an intrinsic membrane protein with 13 transmembrane domains and it takes up iodide into the cytosol from the extracellular fluid. By transferring NIS function to various cells via gene transfer, the cells can be visualized with gamma or positron emitting radioisotopes such as Tc-99m, I-123, I-131, I-124 and F-18 tetrafluoroborate, which are accumulated by NIS. They can also be treated with beta- or alpha-emitting radionuclides, such as I-131, Re-186, Re-188 and At-211, which are also accumulated by NIS. This article demonstrates the diagnostic and therapeutic applications of NIS as a radionuclide-based reporter gene for trafficking cells and a therapeutic gene for treating cancers.

Keywords: sodium iodide symporter, molecular imaging, radionuclide-based imaging, gene therapy, radionuclide.

Citation styles

©2024 Ivyspring International Publisher. Terms of use